Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXIM002 in Relapsed or Refractory B Cell-Mediated Autoimmune Diseases
NCT07322718Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RXIM002 in systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc) and 4 more, sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 52 weeks and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
RXIM002
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)systemic sclerosis (SSc)immune thrombocytopenia (ITP)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07322718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322718.